证券代码：300573 证券简称：兴齐眼药 公告编号：2025-060 沈阳兴齐眼药股份有限公司 关于变更公司住所并修订公司章程的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）于 2025 年 12 月 1 日召开 了第五届董事会第十四次会议，审议通过了《关于变更公司住所并修订公司章程 的议案》，本议案尚需提交公司股东会审议。现将有关事宜公告如下： 一、变更公司住所情况 结合公司经营发展需要，公司拟变更住所，具体如下： 变更前公司住所：中国（辽宁）自由贸易试验区沈阳片区新运河路 25 号 变更后公司住所：辽宁省沈阳市浑南区新运河路 25 号 | 序号 | | 原《公司章程》 | | 修订后的《公司章程》 | | --- | --- | --- | --- | --- | | | 第五条 公司住所：中国（辽宁）自由贸 | | 第五条 | 公司住所：辽宁省沈阳市浑南区 | | 1 | 易试验区沈阳片区新运河路 | 25 号。 | 新运河路 | 25 号。 | | | | 邮政编码：110167。 | 邮政编码：1 ...

一、召开会议的基本情况 证券代码：300573 证券简称：兴齐眼药 公告编号：2025-061 沈阳兴齐眼药股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司(以下简称"公司")于 2025 年 12 月 1 日召 开第五届董事会第十四次会议，决定于 2025 年 12 月 17 日召开公司 2025 年 第三次临时股东会(以下简称"本次会议")。现将本次会议相关事项通知如 下： 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— 创业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及 《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 17 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2025 年 12 月 17 日 9:15-9:2 ...

一、董事会会议召开情况 1、本次董事会由董事长刘继东先生召集，会议通知于 2025 年 11 月 26 日通 过电子邮件的形式送达至全体董事，董事会会议通知中包括会议的相关资料，同 时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 12 月 1 日在公司会议室以现场与通讯会议相结合 的方式召开。 3、本次董事会应到 9 人，实际出席会议人数为 9 人。 4、本次董事会由董事长刘继东先生主持，公司高级管理人员列席了本次董 事会。 证券代码：300573 证券简称：兴齐眼药 公告编号：2025-059 沈阳兴齐眼药股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 表决结果：9 票赞成，0 票反对，0 票弃权。 （二）审议通过《关于召开公司 2025 年第三次临时股东会的议案》 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、董事会会议审议情况 会议审议并通过了如下议案： （一）审议通过《关于变更公司住所并修订公司章程的议案》 同意公司住 ...

Core Points - The company, Xingqi Eye Medicine, announced that it has received the drug registration certificate for Oubukain Hydrochloride Eye Drops from the National Medical Products Administration [2] Group 1 - The approval of the drug registration certificate is a significant milestone for the company, indicating regulatory compliance and potential market entry [2] - The product, Oubukain Hydrochloride Eye Drops, is expected to enhance the company's product portfolio and may lead to increased revenue opportunities [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Oubakain Hydrochloride Eye Drops, indicating a significant advancement in its product offerings in the ophthalmic field [1] Group 1: Product Approval - The approved product is Oubakain Hydrochloride Eye Drops, which contains Oubakain Hydrochloride as the active ingredient [1] - This eye drop formulation is a single-dose product that does not contain any preservatives [1] - The indication for this product is for surface anesthesia in the field of ophthalmology [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its drug, Oubakain Hydrochloride Eye Drops, which is intended for surface anesthesia in ophthalmology [1] Company Summary - The approved product is a single-dose formulation that does not contain preservatives [1] - The active ingredient in the eye drops is Oubakain Hydrochloride [1] - This approval marks a significant milestone for the company in expanding its product offerings in the ophthalmic field [1]

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-058 沈阳兴齐眼药股份有限公司 药品通用名称：盐酸奥布卡因滴眼液 英文名/拉丁名：Oxybuprocaine Hydrochloride Eye Drops 剂型：眼用制剂 规格：0.4%（0.5ml：2mg） 注册分类：化学药品 4 类 药品注册标准编号：YBH28692025 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 今日，沈阳兴齐眼药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的盐酸奥布卡因滴眼液《药品注册 证书》。现将有关事宜公告如下： 一、药品基本情况 二、药品的其他相关情况 本品是以盐酸奥布卡因为活性成份的滴眼液，公司本次获批的盐酸奥布卡因 滴眼液为不含抑菌剂单剂量产品，适应症为眼科领域内的表面麻醉。原研药品已 进口中国。截至目前，国内已有同品种仿制药获批上市。 1 三、风险提示 上市 ...

Core Viewpoint - The company emphasizes that its stock price is influenced by various factors, including market environment, industry trends, investor preferences, and expectations [1] Group 1: Company Strategy - The management is committed to improving operational performance through steady operations and fulfilling information disclosure obligations [1] - The company actively communicates its investment value to the market and aims to provide stable and long-term value returns to shareholders [1] Group 2: Investor Relations - The company focuses on enhancing investor communication and has a strategy of continuous and stable cash dividends to reward investors [1] - Future efforts will include optimizing management practices and improving governance structures to ensure consistent value returns for shareholders [1]

Investment Rating - The report indicates a positive investment outlook for the dry eye disease treatment drug industry, with a projected compound annual growth rate (CAGR) of 10% from 2025 to 2030, and the market size expected to exceed 9.6 billion yuan by 2030 [4][31]. Core Insights - The dry eye disease treatment market in China is characterized by a dual-track competition between foreign and domestic companies, with local firms like Xingqi Eye Medicine and Hengrui Medicine gradually breaking the monopoly of foreign enterprises through independent research and development and collaborative efforts [4][10]. - The number of dry eye disease patients in China has surpassed 360 million, with an annual growth rate of 10%, indicating a continuous expansion of diagnosis and treatment demand [4][11]. - The market is shifting from reliance on traditional treatments like artificial tears to innovative therapies, including immunosuppressants and new drug delivery systems, marking a transition to a more precise and individualized treatment approach [4][17][34]. Summary by Sections Industry Definition - Dry eye disease (DED) is caused by insufficient tear production or instability of the tear film, leading to various ocular discomforts. Treatment is individualized and can include drug therapy, physical therapy, and surgical options [5]. Drug Classification - Dry eye treatment drugs can be categorized based on their mechanisms of action, including lubricating and repairing agents, anti-inflammatory drugs, and antibacterial agents [6][7][8]. Industry Characteristics - The increase in screen time among residents has led to a rise in dry eye disease cases, creating significant market potential. The market is currently dominated by artificial tears and cyclosporine eye drops [10][12]. Market Size and Growth - The market size for dry eye treatment drugs is projected to grow from 12.755 billion yuan in 2025 to 19.306 billion yuan by 2030, with a CAGR of 8.64% [31][34]. Competitive Landscape - The high-end market for dry eye treatment drugs is primarily dominated by foreign brands, but domestic companies are making significant strides through innovation and competitive pricing [41][42][43]. Policy Analysis - Recent policies aim to enhance eye health services and promote awareness of dry eye disease, which is expected to further stimulate market growth [39][40]. Industry Chain Analysis - The industry chain includes upstream raw material suppliers, midstream drug manufacturers, and downstream sales channels, with a focus on innovation and quality improvement to enhance competitiveness [18][19][20].

Core Viewpoint - The upgrade from "Quality Month" to "Quality Season" at Shenyang Xingqi Eye Pharmaceutical Co., Ltd. signifies a comprehensive enhancement in quality management practices, leading to more extensive participation and deeper engagement across the organization [1][2]. Group 1: Activity Structure and Content - The "Quality Season" initiative includes a systematic upgrade in content structure, featuring four core dimensions: quality culture shaping, quality capability enhancement, quality innovation practice, and quality results promotion, with a total of 16 sub-activities planned [1][2]. - New targeted modules have been introduced, such as "Senior Leaders Discuss Culture" to convey the core quality culture from a strategic perspective, and "Quality Management Model Presentation" to optimize quality management methods [2][3]. Group 2: Implementation and Depth - The transition to "Quality Season" was initiated after the previous "Quality Month," with August designated as a planning month to ensure thorough preparation and effective execution of activities [3]. - The activities were designed to extend across various operational units, ensuring that quality awareness and methods are integrated into all aspects of the company's operations, moving from a broad approach to a deeply rooted one [3][4]. Group 3: Participation and Engagement - The "Quality Season" activities emphasized full participation and coverage, with most activities open to all departments, fostering a culture of quality across the organization [5][6]. - Activities such as the Quality Lecture Hall and knowledge competitions were aimed at enhancing employees' understanding of quality standards and regulations, while practical skill competitions provided a platform for hands-on learning [5][6]. Group 4: Recognition and Impact - The company recognized exemplary employees through awards like "Most Beautiful Quality Person" and "EHS Star," aiming to inspire a collective commitment to quality improvement across the organization [6].